JP2014510152A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510152A5
JP2014510152A5 JP2014504014A JP2014504014A JP2014510152A5 JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5 JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5
Authority
JP
Japan
Prior art keywords
formulation
viscosity
acetate
reduced
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032464 external-priority patent/WO2012141978A2/en
Publication of JP2014510152A publication Critical patent/JP2014510152A/ja
Publication of JP2014510152A5 publication Critical patent/JP2014510152A5/ja
Pending legal-status Critical Current

Links

JP2014504014A 2011-04-07 2012-04-06 粘度が低減された処方物 Pending JP2014510152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473123P 2011-04-07 2011-04-07
US61/473,123 2011-04-07
PCT/US2012/032464 WO2012141978A2 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (2)

Publication Number Publication Date
JP2014510152A JP2014510152A (ja) 2014-04-24
JP2014510152A5 true JP2014510152A5 (enExample) 2015-05-21

Family

ID=47009919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504014A Pending JP2014510152A (ja) 2011-04-07 2012-04-06 粘度が低減された処方物

Country Status (12)

Country Link
US (1) US20140044727A1 (enExample)
EP (1) EP2694708A4 (enExample)
JP (1) JP2014510152A (enExample)
KR (1) KR20140066124A (enExample)
CN (1) CN103582724A (enExample)
AU (1) AU2012243126A1 (enExample)
BR (1) BR112013025845A2 (enExample)
CA (1) CA2832560A1 (enExample)
EA (1) EA201391489A1 (enExample)
IL (1) IL228626A0 (enExample)
SG (1) SG193964A1 (enExample)
WO (1) WO2012141978A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2523688T3 (en) * 2010-01-15 2017-12-04 Kirin-Amgen Inc ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS
JP2014516924A (ja) * 2011-04-07 2014-07-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
KR20150032941A (ko) * 2012-06-21 2015-03-31 유씨비 파마, 에스.에이. 약학 제제
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG10201902915VA (en) 2014-10-01 2019-04-29 Eagle Biologics Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
TWI780988B (zh) 2015-08-24 2022-10-11 英商葛蘭素史密斯克藍智慧財產權有限公司 生藥組成物
CN105733250B (zh) * 2016-05-04 2017-12-26 山东省药学科学院 一种交联聚谷氨酸悬浮液及其制备方法与应用
CA3049857A1 (en) * 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
JOP20190255A1 (ar) * 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
SG11202003754YA (en) 2017-05-16 2020-05-28 Bhamis Research Laboratory Pvt Ltd High concentration protein formulations with reduced viscosity
JP7295038B2 (ja) 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CA3118144A1 (en) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
AU2020263318B2 (en) * 2019-04-23 2025-10-23 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2423227C (en) * 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20050164929A1 (en) * 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
AU2003287980B2 (en) * 2002-11-01 2009-06-25 Glaxosmithkline Biologicals S.A. Drying process
JP2006514954A (ja) * 2002-12-31 2006-05-18 ネクター セラピューティクス 抗体含有粒子及び組成物
KR101363777B1 (ko) * 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―13 항체 조성물
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
JP2010532790A (ja) * 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
CA2701032C (en) * 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2515941B1 (en) * 2009-12-21 2019-11-13 F.Hoffmann-La Roche Ag Pharmaceutical formulation of bevacizumab
JP2013525484A (ja) * 2010-05-03 2013-06-20 ジェネンテック, インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法

Similar Documents

Publication Publication Date Title
JP2014510152A5 (enExample)
JP2014516924A5 (enExample)
RU2020123963A (ru) Стабилизированные препараты, содержащие антитела против ngf
JP2013517277A5 (enExample)
JP2019503349A5 (enExample)
JP2020537520A5 (enExample)
JP2013543505A5 (enExample)
IL283424B2 (en) Stabilized formulations that include antibodies against the interleukin receptor (il-4r)
RU2016129624A (ru) Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
CN114616249A (zh) 含有抗pd-l1抗体的稳定制剂
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
MX363226B (es) Formulaciones de anticuerpos.
JP2017515909A5 (enExample)
JP2013535190A5 (enExample)
HRP20192346T1 (hr) Molekule anti-lag-3 antitijela i njihove uporabe
JP2014522843A5 (enExample)
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
AU2019346598A1 (en) Anti- HLA-G antibodies, compositions comprising anti- HLA-G antibodies and methods of using anti- HLA-G antibodies
EA200970880A1 (ru) Стабильные композиции на основе антител
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
AR088455A1 (es) Anticuerpos que antagonizan cd40l
FI3355919T3 (fi) Yhdistelmähoito ihmisen kasvu- ja erilaistumistekijä 15:n (GDF-15) inhibiittoreita ja immuunitarkistuspiste-estäjiä käyttämällä